-16.6%
CRH vs MRNA
+909.7%
-926.2%
-39.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.4% | -6.5% | +3.2% | -3.2% |
| 7D | +5.3% | +8.4% | -3.1% | +5.2% |
| 30D | +14.2% | +28.8% | -14.6% | +13.5% |
| 3M | -4.2% | +329.2% | -333.4% | -9.1% |
| 6M | -14.5% | +416.9% | -431.4% | -20.7% |
| YTD | -22.7% | +718.8% | -741.4% | -28.0% |
| 1Y | -16.6% | +924.9% | -941.4% | -25.0% |
| All | -16.6% | +909.7% | -926.2% | -25.0% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling